摘要：目的:探讨Graves病患者外周血中可溶性CD28分子浓度与FT3、FT4、sTSH和TRAb等实验室参数的相关性,以分析外周血可溶性CD28分子含量测定对Graves病的临床辅助诊断价值。方法:采用双单抗夹心酶联检测法分析Graves病患者血液中可溶性CD28分子的含量;化学发光免疫法检测血液中甲状腺功能指标FT3、FT4、sTSH的浓度;ELISA法测定血液中TRAb的含量。结果:Graves病人血液中可溶性CD28分子含量(3.42 ± 0.74 ng/ml)明显高于健康对照组(0.83 ± 0.29 ng/ml) (p ;患者体内可溶性CD28分子的表达水平与FT3、FT4和TRAb浓度均呈正相关关系,相关系数γ分别为0.786、0.746和0.734,但可溶性CD28分子浓度与血清TSH表达呈显著负相关,相关系数γ为?0.719;外周血液中可溶性CD28分子与Graves病患者甲状腺的肿大程度(p 和突眼症(p 均具有显著的正相关关系。结论:可溶性CD28分子参与了Graves疾病发生发展的病理过程,与FT3、FT4、sTSH和TRAb均具有较好的相关性,可作为Graves病临床辅助诊断和疗效评估的重要生物学参数。 Objective: We did this research to discuss the clinical importance of measuring plasma soluble CD28 in Graves’ disease, and explore correlation of soluble CD28 and FT3, FT4, sTSH, TRAb of plasma from Graves disease, and analyze diagnostic value of soluble CD28 in Graves’ disease. Me- thods: Using the sandwich ELISA for detecting soluble CD28 and TRAb levels in plasma from healthy donors and patients with Graves’ disease, we analyze the concentrations of FT3, FT4, sTSH through chemiluminescence immunoassay, simultaneously. Results: Our results have suggested that mean concentrations of soluble CD28 detected in patients with Graves’ disease (3.34 ± 0.62 ng/ml) were significantly higher than those in healthy subjects (0.76 ± 0.21 ng/ml) (p r = 0.786, p 0.01), FT4 (r = 0.746, p 0.01), and TRAb (r = 0.734, p 0.01) in plasma, but negative correlation was found between sCD28 levels and serum TSH (r = ?0.719, p 0.01). High soluble CD28 levels (5 ng/ml) in plasma of peripheral blood of some Graves patients had significant positive correlation with goiter (p p
